Peritoneal (Abdominal Mesothelioma)
Comprehensive Treatment Algorithms of the Swiss Peritoneal Cancer Group for Peritoneal Cancer of Gastrointestinal Origin
Cancers 2022 September 1 [Link] Michel Adamina, Maxime Warlaumont, Martin D Berger, Silvio Däster, Raphaël Delaloye, Antonia Digklia, Beat Gloor, Ralph Fritsch, Dieter Koeberle, Thibaud Koessler, Kuno Lehmann, Phaedra Müller, Ralph Peterli, Frédéric Ris, Thomas Steffen, Christian Stefan Weisshaupt, Martin Hübner Abstract Peritoneal cancer (PC) is a dire finding, yet in selected patients, long-term survival…
Read MoreMalignant Peritoneal Mesothelioma Presenting with High Protein, High Serum-Ascites Albumin Gradient
Case Reports Cureus 2022 July 26 [Link] Zachary P Kerosky, Charleston R Powell, Phillip C Lindholm Abstract Mesothelioma is a difficult-to-detect neoplasm that rarely develops in the peritoneum. In patients with unexplained ascites, pleural fluid analysis and ultrasonography is often the first step to achieving a diagnosis. This case report shares a unique presentation in…
Read MorePSO-Based Evolutionary Approach to Optimize Head and Neck Biomedical Image to Detect Mesothelioma Cancer
Biomed Research International 2022 August 5 [Link] Sheeba Praveen, Neha Tyagi, Bhagwant Singh, Girija Rani Karetla, Meenakshi Anurag Thalor, Kapil Joshi, Melkamu Tsegaye Abstract Mesothelioma is a form of cancer that is aggressive and fatal. It is a thin layer of tissue that covers the majority of the patient’s internal organs. The treatments are available;…
Read MoreFDG PET/CT for Staging and Restaging Malignant Mesothelioma
Seminars in Nuclear Medicine 2022 August 11 [Link] Egesta Lopci, Angelo Castello, Luigi Mansi Abstract Malignant mesothelioma is an aggressive tumor originating from the mesothelial cells and presenting in general with a very poor prognosis. The pleural localization represents the prevailing disease site, while peritoneal involvement is commonly rare. The WHO classifies mesotheliomas into epithelioid,…
Read MoreDiagnostic capacity of BAP1 and MTAP in cytology from effusions and biopsy in mesothelioma
Journal of the American Society of Cytopathology 2022 July 9 [Link] Louise Andersen Lynggård, Vasiliki Panou, Weronika Szejniuk, Oluf Dimitri Røe, Christos Meristoudis Abstract Introduction: Serous effusion is often the first sign of mesothelioma. Diagnosis based on cytologic material from the effusions remains controversial and complementary biopsy is usually required. However, obtaining representative tissue sample…
Read MoreEfficacy and Adverse Events of Apatinib Salvage Treatment for Refractory Diffuse Malignant Peritoneal Mesothelioma: A Pilot Study
Frontiers in Oncology 2022 July 1 [Link] Zhi-Ran Yang, Yan-Dong Su, Ru Ma, He-Liang Wu, Yan Li Abstract Objective: To investigate the clinical efficacy and adverse events (AEs) of apatinib salvage treatment for diffuse malignant peritoneal mesothelioma (DMPM) that has failed to respond to the recommended treatments. Methods: 27 patients with refractory DMPM were treated…
Read MoreSubstance GP-2250 as a New Therapeutic Agent for Malignant Peritoneal Mesothelioma-A 3-D In Vitro Study
International Journal of Molecular Science 2022 June 30 [Link] Claudia Baron, Marie Buchholz, Britta Majchrzak-Stiller, Ilka Peters, Daniel Fein, Thomas Müller, Waldemar Uhl, Philipp Höhn, Johanna Strotmann, Chris Braumann Abstract Malignant peritoneal mesothelioma is a rare tumor entity. Although cytoreductive surgery and hyperthermic intraperitoneal chemotherapy have increased overall survival, its prognosis remains poor. Established chemotherapeutics…
Read MorePrognostic factors of malignant peritoneal mesothelioma: a retrospective study of 52 female patients
World Journal of Surgical Oncology 2022 June 29 [Link]Jianting Ma, Shengzhi Zhang Abstract Background: Prognosis in malignant peritoneal mesothelioma (MPM) remains poor, and the associated factors are unclear. Therefore, this study aimed to investigate the prognostic factors of MPM. Methods: A total of 52 female MPM patients treated in 2012-2017 were retrospectively analyzed. Kaplan-Meier survival…
Read MoreIntraperitoneal paclitaxel for patients with primary malignant peritoneal mesothelioma: a phase I/II dose escalation and safety study-INTERACT MESO
BMJ Open 2022 June 22 [Link] Job P van Kooten, Michelle V Dietz, Niels A D Guchelaar, Alexandra R M Brandt-Kerkhof, Stijn L W Koolen, Jacobus W A Burger, Ron H J Mathijssen, Cornelis Verhoef, Joachim G J V Aerts, Eva V E Madsen Abstract Introduction: Malignant peritoneal mesothelioma (MPM) is a rare, aggressive tumour…
Read MoreMolecular Characterization of Mesothelioma: Impact of Histologic Type and Site of Origin on Molecular Landscape
JCO Precision Oncology 2022 June [Link] Ibiayi Dagogo-Jack, Russell W Madison, Jochen K Lennerz, Kuei-Ting Chen, Julia F Hopkins, Alexa B Schrock, Lauren L Ritterhouse, Ashley Lester, Keith A Wharton Jr, Mari Mino-Kenudson, Natalie Danziger, Yin P Hung, Douglas A Mata, Jeffrey S Ross Abstract Purpose: Mesothelioma is an aggressive malignancy with heterogeneous outcomes that…
Read More